SCHEMBL19726326

SCHEMBL19726326

CCOC(=O)C1=CCN(S(=O)(=O)c2cccc(F)c2)C1c1ccc(C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.42
TSHR P16473 3/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 5/20 0.41
GAA P10253 3/20 0.41
HCRTR2 O43614 1/20 0.41
PTGDR Q13258 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
NOD2 Q9HC29 2/20 0.40
NOD1 Q9Y239 2/20 0.40
BCHE P06276 2/20 0.40
ACHE P22303 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TLR4 O00206 1/20 0.39
USP2 O75604 1/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19726316 0.95 BCHE (0.44) L3MBTL1ALDH1A1GAAPTGDRPTGDR2
SCHEMBL23775963 0.92 USP2 (0.43) L3MBTL1KDM4EALDH1A1GAAPTGDR
SCHEMBL23775965 0.92 ACHE (0.47) L3MBTL1TSHRLMNAKDM4EALDH1A1
SCHEMBL25491446 0.91 TSHR (0.47) L3MBTL1TSHRLMNAKDM4EALDH1A1
SCHEMBL23776145 0.89 L3MBTL1 (0.52) L3MBTL1TSHRLMNAKDM4EALDH1A1
SCHEMBL23776239 0.89 TSHR (0.52) L3MBTL1TSHRLMNAKDM4EALDH1A1
SCHEMBL23775898 0.87 NOD2 (0.41) L3MBTL1ALDH1A1GAAPTGDRPTGDR2
SCHEMBL25491424 0.87 LMNA (0.50) L3MBTL1TSHRLMNAKDM4EALDH1A1
SCHEMBL23776101 0.87 TLR4 (0.41) L3MBTL1TSHRALDH1A1GAAPTGDR
SCHEMBL23776098 0.86 NOD2 (0.48) L3MBTL1TSHRALDH1A1GAANOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM WAVEBREAK INC (US) 2024-06-27 US disclosed
US-20170362173-A1 ANTI-ARRHYTHMICITY AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362173-A1 ANTI-ARRHYTHMICITY AGENTS KCNH1, TNNI3, TNNC1 L3MBTL1 2548/4885TSHR 3461/4885LMNA 753/4885
US-20240207270-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM CPT2, PC, SREBF2 L3MBTL1 2839/4885TSHR 3831/4885LMNA 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.